[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100504760":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":19,"responsibleParty":32,"collaborators":34,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":39,"sex":45,"minAge":46,"maxAge":7,"enrollmentInfo":47,"targetDuration":50,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":7,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"German Cancer Research Center","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Stefan Fröhling, M.D.","PRINCIPAL_INVESTIGATOR",[13],{"name":14,"role":15,"phone":16,"phoneExt":17,"email":18},"Richard F Schlenk, M.D.","CONTACT","+49 6221","560","richard.schlenk@nct-heidelberg.de",[20],{"facility":5,"status":21,"city":22,"state":7,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":7},"RECRUITING","Heidelberg","69120","Germany","DE",{"type":27,"coordinates":28},"Point",[29,30],8.69079,49.40768,{"lat":30,"lon":29},{"type":33,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[35],{"name":36,"class":6},"German Consortium for Translational Cancer Research","100504760","molecularly-aided-stratification-for-tumor-eradication-research-100504760",false,"NCT05852522","Molecularly Aided Stratification for Tumor Eradication Research","NCT MASTER Plattform Molecularly Aided Stratification for Tumor Eradication Research","NCT-MASTER","Inclusion Criteria:\n\nRare cancer (Incidence \\\u003C6\u002F100,000 persons\u002Fyear) or Rare subtype of a more common entity (case-by-case decision; example: pancreatic ductal adenocarcinoma without KRAS mutation)\n\nMetastatic and\u002For locally advanced cancer with no curative therapy option and indication for systemic therapy\n\nExclusion Criteria:\n\nSevere neurological or psychiatric disorder interfering with the ability to give oral and written informed consent","ALL","18 Years",{"count":48,"type":49},10000,"ESTIMATED","10 Years","OBSERVATIONAL","NCT\u002FDKFZ\u002FDKTK MASTER is a prospective, continuously recruiting, multicenter observational study for biology-guided stratification of adults with rare cancers, including rare subtypes of common entities, using comprehensive molecular profiling, and clinical decision-making in a multidisciplinary molecular tumor board.",[54,55],"Rare Cancers","Multiomics","2025-02-28",{"date":58,"type":59},"2025-03-04","ACTUAL",{"date":61,"type":59},"2018-11-11",{"date":63,"type":49},"2029-10",{"name":5,"class":6},1]